Eligard Injection, Suspension, Extended Release
Product Images NDC 62935-756

Product Visual Gallery

This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Eligard (NDC 62935-756). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tolmar Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mixing (Eligard Pss All Strengths 1)

An instructional diagram showing the tray contents and components under the tray for a medication injection system. The tray contents include Syringe A, Syringe B, and a coupling device with a latching button connecting the syringes. Under the tray are a safety needle with cap, consisting of a needle hub, safety shield, and cap.*

FDA Label Image

Admin (Eligard Pss All Strengths 10)

An instructional diagram showing two methods to activate the Eligard injection device. The left side illustrates bending the syringe to produce a "Click" to prepare for injection, while the right side shows twisting the cap to achieve the same "Click" activation. The images focus on hand positioning and the device's activation mechanism.*

FDA Label Image

Structure (Eligard Pss All Strengths 11)

Chemical structure diagram of leuprolide acetate, the active ingredient in Eligard injection suspension, extended release.*

FDA Label Image

Fig 1 (Eligard Pss All Strengths 12)

A line graph depicting serum concentrations of testosterone (ng/dL) and leuprolide (ng/mL) over a study period of three months. The testosterone levels decrease sharply initially and then stabilize below the clinical castration threshold of 50 ng/dL. Leuprolide concentrations decline more gradually over time. The graph includes error bars representing the mean ± SEM.*

FDA Label Image

Fig 2 (Eligard Pss All Strengths 13)

A graph showing serum concentration levels over a 6-month study period. It compares testosterone levels (ng/dL) and leuprolide levels (ng/mL) with a marked clinical castration threshold at 50 ng/dL. The chart tracks changes in mean serum concentrations with error bars representing SEM, illustrating the pharmacokinetics of the drug over time.*

FDA Label Image

Fig 3 (Eligard Pss All Strengths 14)

A line graph depicting serum concentrations of testosterone and leuprolide over an 8-month study period. The y-axis is on a logarithmic scale showing serum concentration in ng/dL or ng/mL, and the x-axis represents study months. Testosterone levels decrease and stabilize near a clinical castration threshold, while leuprolide levels show a corresponding trend.*

FDA Label Image

Figure 4 (Eligard Pss All Strengths 15)

A line graph depicting serum testosterone concentration (ng/dL) over six months post baseline. The x-axis represents months post baseline, while the y-axis represents serum testosterone concentration. Six injections are marked on the timeline, showing a rapid decline in testosterone levels after the first injection and sustained low levels throughout the six months.*

FDA Label Image

Figure 5 (Eligard Pss All Strengths 16)

A line graph showing serum testosterone concentration (ng/dL) plotted against months post baseline, illustrating a sharp decline in testosterone levels after the first injection and a maintained low level following the second injection around month 3, with measurements spanning 6 months.*

FDA Label Image

Figure 6 (Eligard Pss All Strengths 17)

A line graph showing serum testosterone concentration (ng/dL) over 8 months post baseline, with two indicated injections at months 0 and 4. The plot illustrates a rapid decrease in serum testosterone after the first injection and stable low levels thereafter.*

FDA Label Image

Mixing (Eligard Pss All Strengths 18)

An instructional diagram showing the tray contents and components under the tray for Eligard injection. The tray contents illustration labels Syringe A, Syringe B, and a coupling device with a latching button connecting both syringes. The under the tray section shows a labeled safety needle assembly with needle hub, safety shield, and cap.*

FDA Label Image

Step 2 (Eligard Pss All Strengths 19)

An instructional diagram showing the assembly of two syringes, labeled Syringe A and Syringe B. A hand is depicted pressing down on the coupling device with a latching button that connects the two syringes, demonstrating how to properly join them.*

FDA Label Image

Step2 (Eligard Pss All Strengths 2)

An instructional diagram showing two syringes labeled Syringe A and Syringe B being connected via a coupling device with a latching button indicated. The illustration highlights the assembly step for preparing an injection device.*

FDA Label Image

Step 3 (Eligard Pss All Strengths 20)

An instructional diagram showing two syringe plungers labeled Push A and Push B indicating a back-and-forth motion. A cycle is completed by pushing A then B, repeated 60 times. This illustrates the mixing or preparation procedure for Eligard injection suspension before administration.*

FDA Label Image

Step 4 (Eligard Pss All Strengths 21)

Illustration showing assembly of two syringes labeled Syringe A and Syringe B. A hand is holding each syringe while the plunger of Syringe A is being pushed down into Syringe B, indicating a step in preparation of the medication for subcutaneous injection.*

FDA Label Image

Step 5 (Eligard Pss All Strengths 22)

An instructional illustration showing two syringes labeled A and B being connected and manipulated by hands, with an upward arrow indicating movement of Syringe A away from Syringe B. This likely depicts a preparation step for Eligard injection, suspension, extended release subcutaneous administration.*

FDA Label Image

Step 6 (Eligard Pss All Strengths 23)

An instructional black-and-white illustration showing a gloved hand pressing down on the plunger of Syringe B while another hand holds the syringe barrel. The image demonstrates a step in the administration or preparation process involving a syringe labeled 'Syringe B.'*

FDA Label Image

Step 7 (Eligard Pss All Strengths 24)

An instructional illustration showing a hand holding a syringe labeled 'Syringe B' with the needle pointing upwards, demonstrating a step in the medication administration or preparation process. The image emphasizes syringe handling technique.*

FDA Label Image

Admin 1 (Eligard Pss All Strengths 25)

An illustration showing a hand pinching the skin on the inner side of a forearm, likely demonstrating the proper technique for administering a subcutaneous injection.*

FDA Label Image

Admin (Eligard Pss All Strengths 26)

An instructional illustration demonstrating the subcutaneous injection technique. The image shows a hand holding a syringe with a needle inserted at a 90-degree angle into the skin, indicated by a right-angle symbol. The other hand is pinching the skin to prepare for injection.*

FDA Label Image

Admin (Eligard Pss All Strengths 27)

An instructional diagram showing two hands preparing a prefilled syringe for administration. Both frames depict movements indicated by the word "Click" and arrows, illustrating the steps to unlock or prepare the syringe cap for injection. The image is related to Eligard injection use.*

FDA Label Image

7.5 mg Carton (Eligard Pss All Strengths 28)

Eligard 7.5 mg injectable suspension for subcutaneous injection carton label by TOLMAR Inc. This single-dose package contains a 7.5 mg extended-release suspension of leuprolide acetate designed for monthly administration. The label includes dosing instructions, storage information, and a barcode, featuring blue and white colors with the Eligard logo.*

FDA Label Image

7.5 mg Carton (Eligard Pss All Strengths 29)

Flat packaging carton for Eligard, an injection suspension extended release containing leuprolide acetate by TOLMAR Inc. The design includes a blue panel urging users to review instructions before use and mentions an OR code to scan for detailed preparation guidance. The carton layout shows flaps and fold lines for assembly but does not specify strength or detailed ingredient information.*

FDA Label Image

Step3 (Eligard Pss All Strengths 3)

An instructional diagram showing the use of a syringe with a plunger and a stopper sliding inside the barrel. It depicts pushing forward (Push A) and pulling back (Push B) actions to be alternated for one cycle, repeated 60 times. The illustration is likely part of medication preparation or reconstitution steps.*

FDA Label Image

22.5 mg Carton (Eligard Pss All Strengths 30)

The packaging label for Eligard 22.5 mg injection, suspension, extended release, subcutaneous use, by TOLMAR Inc. The label indicates dosing every 3 months and includes product details such as single-dose packaging, NDC 62935-227-10, and instructions for use. The label mentions components like a syringe system and delivery system and emphasizes reconstitution and healthcare provider administration.*

FDA Label Image

22.5 mg Carton (Eligard Pss All Strengths 31)

Flat packaging label for Eligard, an injection suspension extended-release product containing leuprolide acetate. The label includes a QR code with instructions to scan for usage guidance and a green section advising users to see instructions for use. The label is unassembled and shows fold and cut lines.*

FDA Label Image

30 mg Carton (Eligard Pss All Strengths 32)

Eligard 30 mg for injectable suspension (leuprolide acetate) extended-release subcutaneous injection, in single-dose packaging by TOLMAR Inc. The box indicates a 4-month dosing interval and includes contents such as pre-connected syringes for reconstitution. The label provides storage and usage instructions, NDC 62935-306-40, and regulatory information.*

FDA Label Image

30 mg Carton (Eligard Pss All Strengths 33)

Packaging label for Eligard injection, suspension, extended release by TOLMAR Inc. The label includes a purple panel instructing users to read the box and guide before use and mentions Eligard RD. A QR code is present for scanning instructions. The label is a die-cut flat layout for folding into a carton.*

FDA Label Image

Step4 (Eligard Pss All Strengths 4)

An instructional illustration showing two syringes labeled Syringe A and Syringe B being connected, with an arrow indicating that Syringe A is being inserted into Syringe B. A hand holds each syringe, demonstrating the assembly or transfer process.*

FDA Label Image

Step5 (Eligard Pss All Strengths 5)

An instructional diagram showing hands preparing two syringes labeled A and B. Syringe A is being pulled upward while Syringe B is held steady and turned, indicating a step in medication preparation or administration technique.*

FDA Label Image

Step6 (Eligard Pss All Strengths 6)

Illustration showing hands handling a syringe labeled as Syringe B, demonstrating the proper technique for engaging or manipulating the syringe plunger or cap.*

FDA Label Image

Step7 (Eligard Pss All Strengths 7)

An instructional line drawing showing a hand holding a syringe labeled 'Syringe B' with an arrow pointing upward, indicating the syringe is being pulled or removed from a vial or container below. The image is presumably part of preparation instructions for Eligard injection suspension.*

FDA Label Image

Admin1 (Eligard Pss All Strengths 8)

An instructional illustration showing a person's hand pinching the skin on an arm, demonstrating a step likely related to subcutaneous injection technique for administering Eligard (Leuprolide acetate) extended-release suspension.*

FDA Label Image

Admin (Eligard Pss All Strengths 9)

An instructional illustration showing a hand injecting a subcutaneous injection at a 90-degree angle into skin or tissue. A syringe is held by one hand with the needle inserted, while the other hand is stabilizing the skin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.